# Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.

> **NCT03724071** · PHASE1,PHASE2 · TERMINATED · sponsor: **Transgene** · enrollment: 51 (actual)

## Conditions studied

- Colorectal Neoplasm
- Digestive System Neoplasm

## Interventions

- **BIOLOGICAL:** TG6002
- **DRUG:** Flucytosine (5-FC, Ancotil)

## Key facts

- **NCT ID:** NCT03724071
- **Lead sponsor:** Transgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-16
- **Primary completion:** 2023-02-23
- **Final completion:** 2023-02-23
- **Target enrollment:** 51 (ACTUAL)
- **Why stopped:** Study has been terminated after Phase I part on 23 February 2023
- **Last updated:** 2023-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03724071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03724071, "Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03724071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*